COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?

Stefano Gelibter; Mario Orrico; Massimo Filippi; Lucia Moiola

doi:10.1016/j.msard.2021.102775

Related publications

Article2020

COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience

Paolo Preziosa, Maria A. Rocca, Agostino Nozzolillo, Lucia Moiola, Massimo Filippi

Preprint2020

COVID-19 in Teriflunomide-Treated Patients with Multiple Sclerosis

Amir‐Hadi Maghzi, Maria K. Houtchens, Paolo Preziosa, Carolina Ionete, Biljana Beretich, James Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara HW Schwartz, Jacob A. Sloane, Mark S. Freedman, Massimo Filippi, Howard L. Weiner, Rohit Bakshi

Article2020

COVID-19 in teriflunomide-treated patients with multiple sclerosis

Amir Hadi Maghzi, Maria K. Houtchens, Paolo Preziosa, Carolina Ionete, Biljana Beretich, James Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara Schwartz, Jacob A. Sloane, Mark S. Freedman, Massimo Filippi, Howard L. Weiner, Rohit Bakshi

Article2023

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4

Diego Centonze, Maria Pia Amato, Vincenzo Brescia Morra, Eleonora Cocco, Nicola De Stefano, Claudio Gasperini, Paolo Gallo, Carlo Pozzilli, María Trojano, Massimo Filippi

Article2025

Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab

Lucia Moiola, Alessandra Mandelli, Maciej Tarkowski, Annamaria Finardi, Arianna Gabrieli, Chiara Zanetta, Vittorio Viti, Irene Gattuso, Federica Esposito, Rosetta Pedotti, Erwan Muros‐Le Rouzic, Catarina Raposo, Maria A. Rocca, Massimo Locatelli, Chiara Bonini, Roberto Furlan, Agostino Riva, Massimo Filippi